

List of transitional WLAs (in alphabetical order)

tWLA			
National Regulatory Authority		Origin of transition <i>As per WHO interim list at 31/03/2022¹</i>	Scope of tWLA designation
		A ML3/ML4 NRAs (medicines and/or vaccines) ³ B SRA (medicines) ⁴ C Highly performing NRA (vaccines) ⁵ D NRAR of the Americas (medicines and/or vaccines) ⁶ E Functional NRA (vaccines) ⁷	<input type="checkbox"/> Medicines ² <input type="checkbox"/> Vaccines
1.	Argentina ANMAT	D	Medicines Vaccines
2.	Australia TGA	B, C, E	Medicines Vaccines
3.	Austria AGES	B	Medicines
4.	Belgium FAMPH	B, C, E	Medicines Vaccines
5.	Brazil ANVISA	D, E	Medicines Vaccines
6.	Bulgaria BDA	B, E	Medicines Vaccines
7.	Canada Health Canada	B, C, D, E	Medicines Vaccines
8.	Chile ISP	D	Medicines
9.	China NMPA	E	Vaccines
10.	Colombia INVIMA	D	Medicines
11.	Croatia HALMED	B	Medicines
12.	Cyprus MoH-PHS	B	Medicines
13.	Cuba CECMED	D, E	Medicines Vaccines
14.	Czech Republic SUKL	B	Medicines
15.	Denmark DKMA	B, E	Medicines Vaccines
16.	Egypt EDA	A (ML3)	Vaccines
17.	Estonia SAM	B	Medicines
18.	Finland FIMEA	B	Medicines
19.	France ANSM	B, C, E	Medicines Vaccines
20.	Germany BfARM PEI	B C, E	Medicines Vaccines
21.	Ghana FDA	A (ML3)	Medicines
22.	Greece EOF	B	Medicines
23.	Hungary OGYEI	B	Medicines
24.	Iceland IMA	B	Medicines

25. India	CDSO	A (ML3)	Vaccines
26. Indonesia	BADAN POM	A (ML3)	Vaccines
27. Iran (Islamic Republic of)	IFDA	E	Vaccines
28. Ireland	HPRA	B	Medicines
29. Italy	AIFA	B, C, E	Medicines Vaccines
30. Japan	PMDA	B, E	Medicines Vaccines
31. Latvia	ZVA	B	Medicines
32. Liechtenstein	Office of Health	B	Medicines
33. Lithuania	VVKT	B	Medicines
34. Luxembourg	MoH	B	Medicines
35. Malta	Medicines Authority	B	Medicines
36. Mexico	COFEPRIS	D, E	Medicines Vaccines
37. Netherlands	MEB	B, C, E	Medicines Vaccines
38. Nigeria	NAFDAC	A (ML3)	Medicines
39. Norway	NOMA	B	Medicines
40. Poland	URPL	B	Medicines
41. Portugal	INFARMED	B	Medicines
42. Republic of Korea	MFDS	E	Vaccines
43. Romania	ANMDMR	B	Medicines
44. Russian Federation	Ministry of Health	E	Vaccines
45. Serbia	ALIMS	A (ML3)	Vaccines
46. Singapore	HSA	A (ML4)	Medicines
47. Slovakia	SUKLO	B	Medicines
48. Slovenia	JAZMP	B	Medicines
49. Spain	AEMPS	B	Medicines
50. Sweden	SMPA	B, E	Medicines Vaccines
51. Switzerland	Swissmedic	B, C, E	Medicines Vaccines
52. Thailand	Thai-FDA	A (ML3)	Vaccines
53. United Kingdom of Great Britain and Northern Ireland	MHRA	B, C, E	Medicines Vaccines
54. United Republic of Tanzania	TMDA	A (ML3)	Medicines
55. United States of America	US-FDA	B, C, D, E	Medicines Vaccines
56. Viet Nam	DAV	A (ML3)	Vaccines
Regional Regulatory System			
1. European Union	EMA/EC	B, C	Medicines Vaccines

- ¹ The time-limited WHO interim list of National Regulatory Authorities was established in September 2019 as part of the planned transformation from the term Stringent Regulatory Authorities (SRAs) to WHO-Listed Authorities (WLA).
- ² Precise scope of designation for tWLAs (new medicines, multisource, biotherapeutics, biosimilar products) will be further defined in agreement with each Regulatory Authority as part of the roadmap to listing.
- ³ National Regulatory Authorities (NRAs) operating at maturity level 3 (ML3) and maturity level 4 (ML4), as benchmarked against the WHO Global Benchmarking Tool (GBT)
- ⁴ Stringent Regulatory Authorities (SRAs) as defined in the [WHO Technical Report Series 1003](#)
- ⁵ NRAs exhibiting high level of performance of WHO's six recommended regulatory functions and exercising full regulatory oversight of any given vaccine ([WHO Technical Report Series 978 Annex 6](#))
- ⁶ Regional Reference Authorities for medicines in the Americas in the Americas (AMRO/PAHO), as assessed against WHO Regional Office for the Americas (AMRO)/Pan American Health Organization (PAHO) standardized evaluation procedure and AMRO/PAHO data collection tool
- ⁷ National Regulatory Authorities (NRAs) benchmarked against the WHO vaccine assessment tool and announced as "functional NRAs" before introduction of the Global Benchmarking Tool (GBT) in 2016